T2	Disorder 52 80	chronic lymphocytic leukemia
N1 	Reference T2 UMLS:C0023434	chronic lymphocytic leukemia
T3	Pharmacological_substance 102 113	alemtuzumab
N1000 	Reference T3 MeSH:D000074323	alemtuzumab
T4	Disorder 158 172	Cryptococcosis
N2 	Reference T4 UMLS:C0010414	Cryptococcosis
T5	Disorder 178 205	disseminated fungal disease
N3 	Reference T5 UMLS:C0026946	disseminated fungal disease
T7	Disorder 401 415	cryptococcosis
N4 	Reference T7 UMLS:C0010414	cryptococcosis
T8	Disorder 421 435	cryptococcemia
T9	Disorder 497 525	fatal C. neoformans fungemia
T10	Disorder 569 597	chronic lymphocytic leukemia
N5 	Reference T10 UMLS:C0023434	chronic lymphocytic leukemia
T11	Pharmacological_substance 611 622	alemtuzumab
N1001 	Reference T11 MeSH:D000074323	alemtuzumab
T12	Disorder 651 672	loss of consciousness
N6 	Reference T12 UMLS:C0041657	loss of consciousness
T13	Pharmacological_substance 698 708	antifungal
N1002 	Reference T13 MeSH:D000935	antifungal
T14	Pharmacological_substance 732 746	amphotericin B
N1003 	Reference T14 MeSH:D000666	amphotericin B
T15	Disorder 787 811	opportunistic infections
N7 	Reference T15 UMLS:C0029118	opportunistic infections
T16	Pharmacological_substance 818 835	immunosuppressive
N1004 	Reference T16 MeSH:D007166	immunosuppressive
T17	Pharmacological_substance 849 860	alemtuzumab
N1005 	Reference T17 MeSH:D000074323	alemtuzumab
T18	Disorder 890 907	fungal infections
N8 	Reference T18 UMLS:C0026946	fungal infections
T21	Disorder 10 46	Cryptococcus neoformans fatal sepsis
T6	Disorder 293 316	Cryptococcus neoformans
N9 	Reference T6 UMLS:C0010414	Cryptococcus neoformans
T24	Disorder 531 542	neutropenic
N10 	Reference T24 UMLS:C0027947	neutropenic
T25	Subject 543 550	patient
T1	Subject 81 88	patient
T19	Subject 373 395	around 20% of patients
T30	Coreferring_mention 628 635	patient
T32	Disorder 677 681	died
N11 	Reference T32 UMLS:C1546956	died
N12 	Reference T32 UMLS:C1306577	died
